S&P 500   2,990.20 (-0.26%)
DOW   26,821.18 (-0.76%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
FB   185.92 (-2.35%)
MSFT   138.05 (-1.17%)
GOOGL   1,245.66 (-0.57%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
NVDA   190.73 (-1.83%)
MU   43.47 (-4.46%)
BABA   170.36 (-3.67%)
GE   8.99 (-0.55%)
AMD   30.81 (-1.06%)
T   38.23 (+1.08%)
NFLX   274.90 (-6.29%)
GILD   64.23 (-1.53%)
DIS   131.27 (-0.83%)
S&P 500   2,990.20 (-0.26%)
DOW   26,821.18 (-0.76%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
FB   185.92 (-2.35%)
MSFT   138.05 (-1.17%)
GOOGL   1,245.66 (-0.57%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
NVDA   190.73 (-1.83%)
MU   43.47 (-4.46%)
BABA   170.36 (-3.67%)
GE   8.99 (-0.55%)
AMD   30.81 (-1.06%)
T   38.23 (+1.08%)
NFLX   274.90 (-6.29%)
GILD   64.23 (-1.53%)
DIS   131.27 (-0.83%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Stemline TherapeuticsAxovant SciencesMyovant SciencesVectura GroupLexicon Pharmaceuticals
SymbolNASDAQ:STMLNASDAQ:AXONNYSE:MYOVOTCMKTS:VEGPFNASDAQ:LXRX
Price Information
Current Price$9.03$1.22$5.20$1.09$3.21
52 Week RangeBuyBuyBuyN/ABuy
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/ABuy
Consensus Price Target$25.20$4.50$24.50N/A$6.75
% Upside from Price Target179.07% upside268.85% upside371.15% upsideN/A110.28% upside
Trade Information
Market Cap$391.42 million$149.18 million$479.48 million$668.13 million$347.49 million
Beta1.411.210.90.380.91
Average Volume836,6491,450,955387,293192,852,458
Sales & Book Value
Annual Revenue$500,000.00N/AN/AN/A$63.21 million
Price / Sales793.92N/AN/AN/A5.40
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.32 per share$0.19 per share$0.06 per shareN/A($0.25) per share
Price / Book6.84N/AN/AN/A-12.84
Profitability
Net Income$-85,020,000.00$-221,570,000.00$-273,550,000.00N/A$-120,550,000.00
EPS($2.99)($2.06)($4.09)N/A($1.14)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/A13.63N/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/A-208.07%
Return on Equity (ROE)-116.58%-416.05%-545.73%N/AN/A
Return on Assets (ROA)-89.96%-124.55%-140.77%N/A-32.82%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.01%1.24%1.24%N/AN/A
Current Ratio4.71%2.02%3.42%N/A5.45%
Quick Ratio4.57%2.02%3.42%N/A5.26%
Ownership Information
Institutional Ownership Percentage82.46%7.58%40.29%N/A98.87%
Insider Ownership Percentage13.10%6.00%3.00%N/A6.40%
Miscellaneous
Employees92N/A86478202
Shares Outstanding43.96 million122.28 million89.62 million612.96 million106.27 million
Next Earnings Date11/14/2019 (Estimated)N/A11/14/2019 (Estimated)N/A11/7/2019 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableOptionable
 Stemline TherapeuticsAxovant SciencesMyovant SciencesVectura GroupLexicon Pharmaceuticals

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel